Patent assignee · FR · COMPANY

CELLECTIS

🏢 View company profile →
97Patents
96Active
97Granted
56Portfolio score

Filing activity: Aug 29, 2002 → Dec 14, 2023 · 10 expiring within 5 years

Most-cited patents

PatentTitleAreaCited byStatus
US7842489B2 Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof Chemistry; Metallurgy 44 Active
US9855297B2 Methods for engineering T cells for immunotherapy by using RNA-guided CAS nuclease system Chemistry; Metallurgy 37 Active
US8802437B2 Meganuclease reagents of uses thereof for treating genetic diseases caused by frame shift/non sense mutations Human Necessities 34 Active
US9890393B2 Methods for engineering T cells for immunotherapy by using RNA-guided CAS nuclease system Chemistry; Metallurgy 25 Active
US8293700B2 Anti-bacterial composition especially for controlling gram-negative bacteria, comprising a peptide and an advantageously hydrophobic anti-bacterial agent Emerging Cross-Sectional Technologies 23 Active
US9944702B2 CD33 specific chimeric antigen receptors for cancer immunotherapy Chemistry; Metallurgy 21 Active
US9944709B2 CD123 specific chimeric antigen receptors for cancer immunotherapy Chemistry; Metallurgy 19 Active
US7897372B2 I-CreI meganuclease variants with modified specificity, method of preparation and uses thereof Human Necessities 17 Active
US10584352B2 Methods for engineering T cells for immunotherapy by using RNA-guided Cas nuclease system Chemistry; Metallurgy 15 Active
US10006052B2 Laglidadg homing endonuclease cleaving the C-C chemokine receptor type-5 (CCR5) gene and uses thereof Chemistry; Metallurgy 13 Active
US10815500B2 Transcription activator-like effector (TALE) fusion protein Chemistry; Metallurgy 13 Active
US10239948B2 Method of engineering multi-input signal sensitive T cell for immunotherapy Chemistry; Metallurgy 11 Active
US10286007B2 Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cells Chemistry; Metallurgy 10 Active
US10000746B2 LAGLIDADG homing endonuclease cleaving the T cell receptor alpha gene and uses thereof Human Necessities 8 Active
US10196608B2 Method for in situ inhibition of regulatory T cells Chemistry; Metallurgy 7 Active
US10316101B2 BCMA (CD269) specific chimeric antigen receptors for cancer immunotherapy Chemistry; Metallurgy 6 Active
US8476072B2 Meganuclease recombination system Chemistry; Metallurgy 6 Active
US10472613B2 Method for modulating car-induced immune cells activity Chemistry; Metallurgy 5 Active
US10363270B2 Methods for engineering allogeneic and immunosuppressive resistant T cell immunotherapy Chemistry; Metallurgy 5 Active
US10709775B2 Cells for immunotherapy engineered for targeting CD38 antigen and for CD38 gene inactivation Chemistry; Metallurgy 5 Active
US10087453B2 Modified diatoms for biofuel production Emerging Cross-Sectional Technologies 4 Active
US10426795B2 Use of preTalpha or functional variant thereof for expanding TCRalpha deficient T cells Chemistry; Metallurgy 4 Active
US8211685B2 I-DmoI derivatives with enhanced activity at 37° C and use thereof Chemistry; Metallurgy 4 Active
US10378026B2 RNA based method to obtain stably integrated retroviral vectors Chemistry; Metallurgy 4 Active
US8426177B2 Meganuclease variants cleaving a DNA target sequence from the mouse ROSA26 locus and uses thereof Human Necessities 4 Active

Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.